Home/Investors/OrbiMed

OrbiMed

Biotech Investor · 41 portfolio companies

Portfolio
41
Combined Value
$484.3M
Focus Areas
41
Top Stage
Pre-clinical

Portfolio Companies

CompanyValuation
Alector$244.3M
Third Harmonic Bio$240M
Lomond Therapeutics
Edge Medical
Zion Pharma
NewBiologix
ReCode Therapeutics
QL Biopharm
Eccogene
CHARM Therapeutics
ImageneBio
Navire Pharma
Vanqua Bio
Helicore Biopharma
Eilean Therapeutics
Verdiva Bio
Renasant Bio
Terremoto Biosciences
Alterome Therapeutics
Brenig Therapeutics
Mondego Bio
GentiBio
Sirius Therapeutics
RayThera
ProLynx
QuantX Biosciences
TransThera Sciences
Biosion
Quaero Life Science
ProfoundBio
Alveus Therapeutics
Mwyngil Therapeutics
Callio Therapeutics
GeneCure
Immunai
OncoTarget
Premia Spine
GenoDx
Alebund Pharmaceutical
IceCure Medical
Mirador Therapeutics